Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn’s Disease

Ustekinumab is a recently introduced biological agent for the treatment of Crohn’s disease. The clinical use of the trough concentration of ustekinumab is not as standardized as that of infliximab. The authors aimed to introduce a measurement method and the results of trough concentrations of usteki...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Yiyoung, Kang, Ben, Kim, Eun Sil, Choe, Yon Ho, Kim, Mi Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275850/
https://www.ncbi.nlm.nih.gov/pubmed/35175246
http://dx.doi.org/10.1097/FTD.0000000000000976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275850/
https://www.ncbi.nlm.nih.gov/pubmed/35175246
http://dx.doi.org/10.1097/FTD.0000000000000976

Ejemplares similares